Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2015 | 03-2014 | 03-2013 | 03-2012 | 03-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,726,115 | 1,184,000 | 1,326,000 | 1,550,000 | N/A |
| Depreciation Amortization | 595,813 | 624,000 | 615,000 | 799,000 | N/A |
| Accounts receivable | 35,599 | -11,000 | 23,000 | N/A | N/A |
| Accounts payable and accrued liabilities | 288,980 | -201,000 | -204,000 | N/A | N/A |
| Other Working Capital | -461,670 | -578,000 | -708,000 | 272,000 | N/A |
| Other Operating Activity | -476,894 | 1,062,000 | 482,000 | -515,000 | 0 |
| Operating Cash Flow | $1,707,943 | $2,080,000 | $1,534,000 | $2,106,000 | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | 122,000 | N/A | N/A |
| PPE Investments | -170,252 | -200,000 | -325,000 | -435,000 | N/A |
| Net Acquisitions | N/A | 181,000 | N/A | -46,000 | N/A |
| Purchase Of Investment | -32,605 | -15,000 | N/A | N/A | N/A |
| Sale Of Investment | 88,625 | 73,000 | 102,000 | N/A | N/A |
| Purchase Sale Intangibles | -518,764 | -261,000 | N/A | N/A | N/A |
| Other Investing Activity | -536,199 | -300,000 | -416,000 | 164,000 | 0 |
| Investing Cash Flow | $-650,432 | $-261,000 | $-517,000 | $-317,000 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | -529,884 | -292,000 | -525,000 | N/A | N/A |
| Dividend Paid | -565,529 | -569,000 | -639,000 | -704,000 | N/A |
| Other Financing Activity | -6,762 | -7,000 | -3,000 | -3,000 | 0 |
| Financing Cash Flow | $-1,102,174 | $-868,000 | $-1,167,000 | $-707,000 | $N/A |
| Exchange Rate Effect | 90,691 | 276,000 | 283,000 | -144,000 | N/A |
| Beginning Cash Position | 3,561,503 | 2,572,000 | 2,685,000 | 2,140,000 | N/A |
| End Cash Position | 3,607,513 | 3,800,000 | 2,818,000 | 3,078,000 | N/A |
| Net Cash Flow | $46,019 | $1,228,000 | $133,000 | $938,000 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,707,943 | 2,080,000 | 1,534,000 | 2,106,000 | N/A |
| Capital Expenditure | -219,847 | -284,000 | -333,000 | N/A | N/A |
| Free Cash Flow | 1,488,096 | 1,796,000 | 1,201,000 | 2,106,000 | 0 |